Biological, molecular, and clinical markers for the diagnosis and typing of lung cancer

Adi F. Gazdar, James L. Mulshine, Barnett S. Kramer

Research output: Chapter in Book/Report/Conference proceedingChapter


Lung cancer is the most common form of cancer as well as the leading cause of cancer deaths in the United States. Approximately 90% of patients eventually die from their disease [1]. Newer forms of therapy are therefore needed. In addition, improvements in our current diagnostic, staging, and typing methodologies would be of benefit. Lung cancer presents a pradoxical situation for the biologist and clinician. While numerous excellent biological and molecular markers are available for tumor tissue diagnosis, typing, and progression, few, if any, have successfully weathered the perilous journey from laboratory to bedside. In this chapter we will discuss the reasons for this paradox, and critically assess the more promising of the many markers clinicians have attempted to use in the management of this disease.

Original languageEnglish (US)
Title of host publicationImmunodiagnosis of Cancer
Subtitle of host publicationSecond Edition
PublisherCRC Press
Number of pages16
ISBN (Electronic)9781351439251
ISBN (Print)9780824782993
StatePublished - Jan 1 2017

ASJC Scopus subject areas

  • Chemistry(all)


Dive into the research topics of 'Biological, molecular, and clinical markers for the diagnosis and typing of lung cancer'. Together they form a unique fingerprint.

Cite this